Omega-3 Fatty Acids Prevent Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome Activation

Immunity

Volumn 38, Issue 6, 2013, Pages 1154-1163

  Yan, Yiqing ^a   Jiang, Wei ^a   Spinetti, Thibaud ^b,c   Tardivel, Aubry ^b   Castillo, Rosa ^b   Bourquin, Carole ^c   Guarda, Greta ^b   Tian, Zhigang ^a   Tschopp, Jurg ^b   Zhou, Rongbin ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 2; DOCOSAHEXAENOIC ACID; G PROTEIN COUPLED RECEPTOR 120; G PROTEIN COUPLED RECEPTOR 40; ICOSAPENTAENOIC ACID; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NLRP3 INFLAMMASOME; OMEGA 3 FATTY ACID; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOINFLAMMATORY DISEASE; CELL MATURATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DIET SUPPLEMENTATION; ENZYME ACTIVATION; ENZYME INHIBITION; GOUT; IN VIVO STUDY; INFLAMMATION; LIPID DIET; MACROPHAGE; METABOLIC DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SALMONELLA TYPHIMURIUM;

ANIMALS; ARRESTINS; CARRIER PROTEINS; CASPASE 1; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ENZYME ACTIVATION; FATTY ACIDS, OMEGA-3; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84879582536     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2013.05.015     Document Type: Article

References (48)

1. Arita M., Ohira T., Sun Y.P., Elangovan S., Chiang N., Serhan C.N. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J.Immunol. 2007, 178:3912-3917.
2. Bohn L.M., Lefkowitz R.J., Gainetdinov R.R., Peppel K., Caron M.G., Lin F.T. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999, 286:2495-2498.
3. Briscoe C.P., Peat A.J., McKeown S.C., Corbett D.F., Goetz A.S., Littleton T.R., McCoy D.C., Kenakin T.P., Andrews J.L., Ammala C., et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br. J. Pharmacol. 2006, 148:619-628.
4. Cintra D.E., Ropelle E.R., Moraes J.C., Pauli J.R., Morari J., Souza C.T., Grimaldi R., Stahl M., Carvalheira J.B., Saad M.J., Velloso L.A. Unsaturated fatty acids revert diet-induced hypothalamic inflammation in obesity. PLoS ONE 2012, 7:e30571.
5. Davis B.K., Wen H., Ting J.P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 2011, 29:707-735.
6. Didierlaurent A., Brissoni B., Velin D., Aebi N., Tardivel A., Käslin E., Sirard J.C., Angelov G., Tschopp J., Burns K. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol. Cell. Biol. 2006, 26:735-742.
7. Dominguez H., Storgaard H., Rask-Madsen C., Steffen Hermann T., Ihlemann N., Baunbjerg Nielsen D., Spohr C., Kober L., Vaag A., Torp-Pedersen C. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J.Vasc. Res. 2005, 42:517-525.
8. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
9. Dyerberg J., Bang H.O. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979, 2:433-435.
10. Endres S., Ghorbani R., Kelley V.E., Georgilis K., Lonnemann G., van der Meer J.W., Cannon J.G., Rogers T.S., Klempner M.S., Weber P.C., et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N.Engl. J. Med. 1989, 320:265-271.
11. Fritsche K. Fatty acids as modulators of the immune response. Annu. Rev. Nutr. 2006, 26:45-73.
12. Gross O., Thomas C.J., Guarda G., Tschopp J. The inflammasome: an integrated view. Immunol. Rev. 2011, 243:136-151.
13. Guarda G., Braun M., Staehli F., Tardivel A., Mattmann C., Förster I., Farlik M., Decker T., Du Pasquier R.A., Romero P., Tschopp J. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34:213-223.
14. Harding H.P., Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 2002, 51(Suppl 3):S455-S461.
15. Herder C., Brunner E.J., Rathmann W., Strassburger K., Tabák A.G., Schloot N.C., Witte D.R. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009, 32:421-423.
16. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., Sugimoto Y., Miyazaki S., Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 2005, 11:90-94.
17. Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 2008, 8:923-934.
18. Hudert C.A., Weylandt K.H., Lu Y., Wang J., Hong S., Dignass A., Serhan C.N., Kang J.X. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. USA 2006, 103:11276-11281.
19. Ichimura A., Hirasawa A., Poulain-Godefroy O., Bonnefond A., Hara T., Yengo L., Kimura I., Leloire A., Liu N., Iida K., et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 2012, 483:350-354.
20. Itoh Y., Kawamata Y., Harada M., Kobayashi M., Fujii R., Fukusumi S., Ogi K., Hosoya M., Tanaka Y., Uejima H., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422:173-176.
21. Kang J.X., Wang J., Wu L., Kang Z.B. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 2004, 427:504.
22. Liou A.P., Lu X., Sei Y., Zhao X., Pechhold S., Carrero R.J., Raybould H.E., Wank S. The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 2011, 140:903-912.
23. Lo J., Bernstein L.E., Canavan B., Torriani M., Jackson M.B., Ahima R.S., Grinspoon S.K. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E102-E109.
24. Mao K., Chen S., Chen M., Ma Y., Wang Y., Huang B., He Z., Zeng Y., Hu Y., Sun S., et al. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Res. 2013, 23:201-212.
25. Martinon F., Pétrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
26. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 2009, 27:229-265.
27. Masters S.L., Dunne A., Subramanian S.L., Hull R.L., Tannahill G.M., Sharp F.A., Becker C., Franchi L., Yoshihara E., Chen Z., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 2010, 11:897-904.
28. Mishra B.B., Rathinam V.A., Martens G.W., Martinot A.J., Kornfeld H., Fitzgerald K.A., Sassetti C.M. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1β. Nat. Immunol. 2013, 14:52-60.
29. Moraes L.A., Piqueras L., Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol. Ther. 2006, 110:371-385.
30. Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996, 45:881-885.
31. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., Li P., Lu W.J., Watkins S.M., Olefsky J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
32. Papin S., Cuenin S., Agostini L., Martinon F., Werner S., Beer H.D., Grütter C., Grütter M., Tschopp J. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 2007, 14:1457-1466.
33. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. J.Clin. Invest. 2006, 116:1802-1812.
34. Robertson R.P., Harmon J., Tran P.O., Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(Suppl 1):S119-S124.
35. Robinson D.R., Urakaze M., Huang R., Taki H., Sugiyama E., Knoell C.T., Xu L., Yeh E.T., Auron P.E. Dietary marine lipids suppress continuous expression of interleukin-1 beta gene transcription. Lipids 1996, 31(Suppl):S23-S31.
36. Rosenvinge A., Krogh-Madsen R., Baslund B., Pedersen B.K. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand. J. Rheumatol. 2007, 36:91-96.
37. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327:296-300.
38. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J.Exp. Med. 2000, 192:1197-1204.
39. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., Moussignac R.L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J.Exp. Med. 2002, 196:1025-1037.
40. Spite M., Norling L.V., Summers L., Yang R., Cooper D., Petasis N.A., Flower R.J., Perretti M., Serhan C.N. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461:1287-1291.
41. Spranger J., Kroke A., Möhlig M., Hoffmann K., Bergmann M.M., Ristow M., Boeing H., Pfeiffer A.F. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
42. Strowig T., Henao-Mejia J., Elinav E., Flavell R. Inflammasomes in health and disease. Nature 2012, 481:278-286.
43. Vandanmagsar B., Youm Y.H., Ravussin A., Galgani J.E., Stadler K., Mynatt R.L., Ravussin E., Stephens J.M., Dixit V.D. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 2011, 17:179-188.
44. Weir G.C., Bonner-Weir S. Five stages of evolving beta-celldysfunction during progression to diabetes. Diabetes 2004, 53(Suppl 3):S16-S21.
45. Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M.T., Brickey W.J., Ting J.P. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 2011, 12:408-415.
46. Zhang M.J., Spite M. Resolvins: Anti-Inflammatory and Proresolving Mediators Derived from Omega-3 Polyunsaturated Fatty Acids. Annual review of nutrition 2012, 32:203-227.
47. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2010, 11:136-140.
48. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.